Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Point-of-Care Flu Test From Mesa Biotech May Head to FDA Next Year

Point-of-Care Flu Test From Mesa Biotech May Head to FDA Next Year

May 23, 2016
|
Madeleine Johnson
Premium

NEW YORK (GenomeWeb) – Aiming for a 2017 launch of its handheld molecular testing device and influenza A/B assay, Mesa Biotech has recently made a number of strategic hires with commercialization and leadership experience.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

German Shepherd's Own Sequence

A German shepherd called Nala has had her genome sequenced.

And Now Serology Tests

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Young at Brain

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

Science Paper Examines Factors to Identify Metastatic Prostate Cancer Responsive to Checkpoint Inhibitors

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Molecular Diagnostics

  1. Luminex Receives FDA Emergency Use Authorization for Second SARS-CoV-2 Assay

  2. With Sputum Test for SARS-CoV-2, MicroGen Dx Aims to Challenge Quest, LabCorp

  3. Thermo Fisher Preliminary Q1 Revenues up 1 to 2 Percent; Firm Withdraws 2020 Guidance

  4. Co-Diagnostics Gets FDA Emergency Use Authorization for Coronavirus Test

  5. FDA Releases New EUA Guidance for MDx Labs Offering SARS-CoV-2 Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.